Indian Court Bars Company from Selling Generic Version of Merck Drug
October 07 2015 - 10:34AM
Dow Jones News
By Suryatapa Bhattacharya
NEW DELHI--The Delhi High Court barred an Indian company from
selling generic versions of a popular diabetes treatment Wednesday
in a rare victory for foreign pharmaceutical companies on
intellectual property rights.
The court ruled that Indian generic-drug company, Glenmark
Pharmaceuticals could no longer sell its version of Merck &
Co.'s Januvia.
The drug is one of the world's most popular treatments for Type
2 diabetes, and generated $3.9 billion in sales last year for
Merck.
Glenmark said it was evaluating its legal options. The company
had been selling generic versions of Januvia in India called Zita
and Zita Met.
Merck's India unit filed a lawsuit in 2013, accusing Glenmark of
infringing on the drug's patent for the drug's main ingredient:
sitagliptin, which works by enhancing the body's ability to lower
blood sugar levels.
The ruling prevents Glenmark from selling, distributing,
advertising and exporting drugs containing this ingredient,
according to the Delhi High Court judgment. The court also ordered
Glenmark to pay an undefined portion of Merck's legal expenses.
Merck's lawyer, Pravin Anand, said the order was a legal victory
for foreign drug companies. India's patent offices and courts have
often declined to defend patents accepted in other countries.
Some of the world's largest pharmaceutical firms like Novartis
AG, Bayer AG and Roche Holding AG, have fought battles to defend
their drugs against Indian generic versions. Novartis lost its
fight to protect leukemia treatment Gleevec from local competition
in 2013.
Critics of foreign drug companies say that they are too eager to
prolong their patents and that they drive up prices for medicine,
putting them out of reach of many Indians.
India has faced criticism from the U.S. for its perceived lax
patent protections.
"This decision will go down well in the U.S. It says that Indian
courts are not influenced by Indian companies and due process was
followed," said Dilip Shah, secretary-general of the Indian
Pharmaceutical Alliance, a trade group.
More such decisions would be bad news for India, said Surajit
Pal, a pharmaceutical analyst at Prabhudas Lilladher, a
Mumbai-based brokerage. Most Indians can't afford patented
medications, he said.
India has one of the highest diabetic populations in the world,
but diabetes treatments remain relatively expensive. The World
Health Organization estimates that a quarter of a family's income
can be spent to treat a single family member with the disease,
compared with 10% in the U.S.
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
October 07, 2015 10:19 ET (14:19 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024